Earnings
Vanda's Hetlios Sales Jumped 289% On Pharmacy Stocking, And The CFO Says They May Fall
Vanda guided to 2026 revenue above $240 million and said cash burn will likely top last year's, with cash at $140.5 million.
VNDA
Vanda Pharmaceuticals (VNDA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Vanda Blames 'Migration To The Mean' As Nereus Vomiting Cut Falls To 27% From 50%
Management says an extreme-vomiter subgroup, 81% in Phase 3 and 83% in Phase 2, shows the drug's effect is reproducible.
Earnings
Vanda Revenue Climbs 24% To $69.8 Million As Spending Drops 18%, But Cash Falls To $140.5 Million
Vanda posted a $22.6 million third-quarter net loss and now expects 2026 revenue above $240 million.
SEC Filings
BlackRock Unit Reports 5.9% Passive Stake In Vanda Pharmaceuticals
BlackRock Portfolio Management holds 3,587,013 Vanda shares, and says it has no aim to influence control of the drugmaker.